a Department of Pharmacology , JSS College of Pharmacy (A Constituent College of Jagadguru Sri Shivarathreeshwara University) , Ootacamund , Tamil Nadu , India.
b Department of Pharmaceutics , JSS College of Pharmacy (A Constituent College of Jagadguru Sri Shivarathreeshwara University) , Ootacamund , Tamil Nadu , India.
Artif Cells Nanomed Biotechnol. 2018 Aug;46(5):885-898. doi: 10.1080/21691401.2017.1366337. Epub 2017 Aug 21.
Breast cancer stem cells (BCSCs) are heterogeneous subpopulation of tumour initiating cells within breast tumours. They are spared even after chemotherapy and responsible for tumour relapse. Targeting BCSCs is, therefore, necessary to achieve radical cure in breast cancer. Despite the availability of agents targeting BCSCs, their clinical application is limited due to their off-target effects and bioavailability issues. Nanotechnology based drug carriers (nanocarriers) offer various advantages to deliver anti-BCSCs agents specifically to their target sites by overcoming their bioavailability issues. In this review, we describe various strategies for targeting BCSCs using nanocarriers.
乳腺癌干细胞(BCSCs)是乳腺癌肿瘤起始细胞中的异质性亚群。即使在化疗后,它们也能幸免,并且是肿瘤复发的原因。因此,靶向 BCSCs 是实现乳腺癌根治的必要条件。尽管有针对 BCSCs 的药物,但由于其脱靶效应和生物利用度问题,其临床应用受到限制。基于纳米技术的药物载体(纳米载体)提供了多种优势,可通过克服其生物利用度问题,将抗 BCSCs 药物特异性递送至其靶位。在这篇综述中,我们描述了使用纳米载体靶向 BCSCs 的各种策略。